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introDuction
Meningiomas represent one third of all primary brain 
tumors. Roughly, 20% of these recur locoregionally after 
initial treatment and require additional treatment. In many 
recurrences, after primary radiotherapy (RT), re-irradi-
ation with or without prior salvage surgery is considered. 
Recurrent meningiomas are thought to have a higher radio 
resistance than tumors controlled after primary treatment, 
therefore, requiring adequate doses in the recurrence situ-
ation for sufficient local control.1,2 However, dose delivery 
is limited by the surrounding organs at risk (OARs) and 
their regeneration potential after an initial course of radi-
ation remains uncertain. One frequently observed sequel 
after intracranial re-irradiation is brain barrier disorder.1,3–5 
It has been suggested, based on animal studies, that brain 
tissue partially repairs damage after an initial course of radi-
ation,6,7 but the radiobiological background of radiation 
damage to the brain and its recovery is not fully understood.
Nevertheless, in a selective group of patients with recur-
rent brain disease, re-irradiation has proven to be a clini-
cally safe and effective treatment.1,4,8–12 Additionally, due to 
the advances in the management of brain tumors, patients' 
life expectancy and general prognosis have substantially 
improved. Therefore, a potentially curative salvage treat-
ment has become necessary for these patients. Conse-
quently, in the last decade, the number of publications on 
re-irradiation has increased to a large body of mainly retro-
spective studies1,3,11–22 and recommendation guidelines 
for the management of glioblastoma and low grade glioma 
have been established.23,24
For intracranial re-irradiation, the aim is not only to 
adequately treat the area of recurrence, but also to reduce 
the total dose to critical OARs within the central nervous 
system as much as possible, e.g. optic nerves and brain-
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objectives: Re-irradiation of recurrent intracranial 
meningiomas represents a major challenge due to dose 
limits of critical structures and the necessity of sufficient 
dose coverage of the recurrent tumor for local control. 
The aim of this study was to investigate dosimetric differ-
ences between pencil beam scanning protons (PBS) and 
volumetric modulated arc therapy (VMAT) photons for 
intracranial re-irradiation of meningiomas.
Methods: Nine patients who received an initial dose 
>50 Gy for intracranial meningioma and who were re-ir-
radiated for recurrence were selected for plan compar-
ison. A volumetric modulated arc therapy photon and 
a pencil beam scanning proton plan were generated 
(prescription dose: 15 × 3 Gy) based on the targets used 
in the re-irradiation treatment.
results: In all cases, where the cumulative dose 
exceeded 100 or 90 Gy, these high dose volumes were 
larger for the proton plans. The integral doses were 
significantly higher in all photon plans (reduction with 
protons: 48.6%, p < 0.01). In two cases (22.2%), organ at 
risk (OAR) sparing was superior with the proton plan. In 
one case (11.1%), the photon plan showed a dosimetric 
advantage. In the remaining six cases (66.7%), we found 
no clinically relevant differences in dose to the OARs.
conclusions: The dosimetric results of the accumulated 
dose for a re-irradiation with protons and with photons 
were very similar. The photon plans had a steeper dose 
falloff directly outside the target and were superior in 
minimizing the high dose volumes. The proton plans 
achieved a lower integral dose. Clinically relevant OAR 
sparing was extremely case specific. The optimal treat-
ment modality should be assessed individually.
advances in knowledge: Dose sparing in re-irradiation 
of intracranial meningiomas with protons or photons is 
highly case specific and the optimal treatment modality 
needs to be assessed on an individual basis.
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this context. Also, several studies have suggested an improved 
outcome, with possible higher doses, in more conformal tech-
niques, i.e. stereotactic RT and stereotactic radiosurgery.20,25,26 
Consequently, proton RT has to be considered for intracranial 
re-irradiation. Theoretically, protons are ideally suited to this 
challenge. Their characteristic Bragg Peak allows for a rapid 
fall-off of the irradiation dose at the distal edge of the target, 
sparing normal tissues that have already received high doses 
from prior RT. In the last decades, several clinical studies have 
been performed for re-irradiation with protons in patients with 
lung cancer, head and neck cancer, esophageal cancer, ependy-
moma, glioma and chordoma.4,8–10,12,16,17,20–24,26–33 Recently, 
a study on reirradiation for intracranial recurrent meningioma 
with particle therapy concluded this was a safe and effective 
treatment.34 The clinical results are positively encouraging with 
respect to tolerance and short-term outcome. Unfortunately, 
only one study, involving proton re-irradiation in rectal cancer 
patients, performed a dosimetric comparison between protons 
and photons.35
Up to today, to our best knowledge, there is no dosimetric eval-
uation of protons vs photons available in the intracranial re-irra-
diation situation. Therefore, we designed this in silico planning 
study to compare protons vs. photons for re-irradiation of recur-
rent meningiomas.
MethoDS anD PatientS
Patients from the Department of Radiation Oncology, Univer-
sity Hospital Zurich, who were treated with an initial dose 
exceeding 50 Gy in 1.8 or 2.0 Gy daily fractions with photons 
and were re-irradiated for a recurrent intracranial meningioma 
were selected. The plans of the initial RT and the re-irradiation 
had to be available in our database. Two new re-irradiation plans 
were prepared, one with photons and one with protons, with 
a dose prescription of 45 Gy in 3-Gy-fractions relative biolog-
ical effectiveness (RBE). For both new plans, the accumulated 
2-Gy-equivalent dose (EQD2) including the initial treatment 
was calculated and a dosimetric analysis was performed.
Structure definition
The planning target volume (PTV) of the original re-irradiation 
was adopted for this planning study. The PTV was defined as the 
gross tumor volume (GTV) delineated on MRI by a radiation 
oncologist including a 3.0 mm margin. In addition, the following 
OARs were delineated for plan dosimetric comparison: brain, 
brain–brainstem, brainstem, chiasm, cochlea, hippocampi, optic 
nerves and pituitary gland.36
Volumetric modulated arc therapy (VMAT) photon 
plan
The field arrangements for the in silico plan were adopted from 
the original clinical re-irradiation plan and consisted of multiple 
non-coplanar 6 MV flattening filter free (FFF) VMAT beams of 
a TrueBeam linear accelerator with a high definition multileaf 
collimator (MLC). The dose was adjusted, and the plan was opti-
mized using the PRO optimizing algorithm in the Eclipse treat-
ment planning system (Varian Medical Systems, Palo Alto, CA, 
USA). The dose calculation was performed with the anisotropic 
analytical algorithm. The calculation grid size was set to 0.15 × 
0.15 cm
Pencil beam scanning proton plan
The proton plans were generated with the Eclipse treatment 
planning system using the ProBeam data provided by Varian. 
The proton plans consisted of 2– to 4 pencil beam spot scanning 
fields using a range shifter with a physical thickness of 5 cm to 
cover superficial target areas at the surface. The detailed beam 
data are shown in Table 1. Intensity modulated optimization was 
performed using the nonlinear universal proton optimizer algo-
rithm. Dose calculation was performed using the proton convo-
lution superposition algorithm.37 Calculation grid size was 0.25 
× 0.25 cm with a slice spacing of 0.3 cm. The proton spot spacing 
was set to 0.425 cm. The sigma of the beam for this proton data 
ranges from 4 to 15 mm in low energies with the 5 cm range 
shifter.38
Dose prescription and optimization
Both plans were optimized to deliver 3.0 Gy (RBE) dose per frac-
tion up to a total of 45.0 Gy (RBE) to the PTV. The plan was 
accepted if 95% of the PTV was covered by more than 95% of 
the prescribed dose. Plans were optimized using normal tissue 
optimization (NTO) and an accepted maximum dose of 48.0 Gy 
(RBE). Nearby critical structures were spared as much as possible 
without compromising the coverage of the target.
Dose accumulation
The initial plan and the new VMAT and proton plans were trans-
ferred to MIM v. 6.6.1 (MIM Software, Cleveland, OH). The 
initial plan had a daily fractionation of 1.8 or 2.0 Gy. For the new 
re-irradiation plans, EQD2 distributions were calculated using 
α/β values of 2 for the spinal cord, brainstem, chiasm and optic 
nerves, and 3 for the remaining normal tissues. Total dose was 
derived by adding the initial dose distribution and the EQD2 of 
the recurrence dose distribution.
Analyses
For the accumulated dose distribution, we analyzed the maximum 
point dose and mean dose to all defined OARs. The accumulated 
doses to these critical structures for all patients are grouped 
and were compared for protons and photons. Additionally, the 
volume receiving more than 100 Gy (V100) outside the PTV 
was determined as well as the volumes receiving 90 Gy (V90) 
and 72 Gy (V72). Furthermore, we analyzed the re-irradiation 
plans with respect to integral dose and the mean total dose to the 
brain excluding the PTV. The integral dose is defined as the mean 
dose received by the body structure multiplied by the volume 
in liters of the body structure. The Wilcoxon signed-ranks test 
was performed for statistical analysis on the whole population. 
Pp-values of less than 0.05 were considered statistically signifi-
cant. Due to the case by case specificity in this patient group, an 
individual comparison of photons vs protons was performed to 
determine in which specific cases protons could be beneficial. All 
statistical analyses were performed with Excel 2016 (Microsoft 
Corporation, Redmond, WA, USA).
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reSultS
Overview of the patients
Nine patients re-irradiated for recurrent meningioma between 
2014 and 2017 were included in this analysis (Table  2). The 
mean age at re-irradiation was 62.9 ± 12.5 years and the mean 
time interval between radiation treatments was 45.3 ± 41.1 
months. Location of the meningioma was convex in five cases 
(55.6%), parafalcine in three cases (33.3%) and tentorial in one 
case (11.1%). The mean PTV was 68.8 ± 49.7 and 43.5 ± 44.5 
ccm for the initial and the secondary plan for recurrent disease, 
respectively. In five out of nine cases (55.6%), there was a partial 
overlap between the initial and the recurrence PTV. The mean 
overlap in these cases was 47.1 ± 21.0%. In the remaining four 
cases (44.4%), the PTV of the recurrence had no overlap with the 
initial PTV (Figure 1). The dose given in the initial treatment was 
60 Gy (30 × 2 Gy) in five cases (55.6%), 59.4 Gy (33 × 1.8 Gy) in 
two cases (22.2%), 54 Gy (30 × 1.8 Gy) in one case (11.1%) and 
52.2 Gy (29 × 1.8 Gy) in one case (11.1%).
Organs at risk
The average mean dose of each specified OAR (Table  3) was 
higher for the accumulated photon plans than for the accumu-
lated proton plans for all nine patients. This difference was statis-
tically significant for brain–-brainstem (15.5 ± 6.8 Gy vs 13.7 ± 
5.8 Gy, p < 0.01), brainstem (8.2 ± 10.0 Gy vs 7.1 ± 9.4 Gy, p < 
0.01), chiasm (13.2 ± 15.9 Gy vs 11.0 ± 13.5 Gy, p < 0.01), left 
optic nerve (10.8 ± 14.4 Gy vs 10.0 ± 13.9 Gy, p < 0.01), right 
optic nerve (13.0 ± 18.4 Gy vs 12.3 ± 18.2 Gy, p < 0.01), left 
hippocampus (9.5 ± 11.7 Gy vs 7.5 ± 11.0 Gy, p < 0.01), pituitary 
gland (15.1 ± 13.9 Gy, p < 0.01) and left cochlea (8.4 ± 14.1 Gy vs 
7.6 ± 14.0 Gy, p < 0.01). The doses to the left hippocampus (14.8 
± 20.7 Gy vs 14.8 ± 24.4 Gy, n.s.) and right cochlea (11.3 ± 20.4 
Gy vs 10.7 ± 20.8 Gy) were not statistically significantly different.
Similarly, the average maximum doses to the OARs (Table  3) 
were statistically significantly lower for the accumulated proton 
plans in most of the analyzed OARs (chiasm: 20.9 ± 24.4 vs 18.5 
± 23.2 Gy, p < 0.01; left optic nerve: 17.6 ± 22.6 vs 16.0 ± 21.8 Gy, 
p < 0.01; left hippocampus: 19.3 ± 20.1 vs 16.2 ± 19.6 Gy, p < 0.01; 
right hippocampus: 24.9 ± 33.4 vs 23.4 ± 33.6 Gy, p < 0.05; pitu-
itary gland: 19.5 ± 24.8 vs 17.6 ± 23.6 Gy, p < 0.01; left cochlea: 
10.1 ± 16.9 vs 9.3 ± 16.8 Gy). There was no statistically significant 
difference (p > 0.05) in average maximum dose to brain–brain-
stem (105.1 ± 20.4 Gy vs 105.3 ± 19.9 Gy, p > 0.1.), brainstem 
(24.3 ± 29.9 Gy vs 21.7 ± 31.8 Gy, p > 0.05), right optic nerve 
(18.8 ± 23.8 Gy vs 18.3 ± 24.7 Gy, p > 0.05) and right cochlea 
(13.0 ± 22.1 Gy vs 12.7 ± 23.7 Gy, p > 0.1).
Looking at the doses to the OARs in each individual case 
(Figure  2), depending on initial tumor and recurrent tumor 
location, more pronounced differences were identified. Espe-
cially in cases number 1, 3 and 6, larger differences in OAR doses 
for brainstem, chiasm, optic nerves, and cochlea were observed. 
In Case 1, the brainstem maximum point dose (39.9 Gy vs 28.0 
Gy), the chiasm maximum point dose (59.3 vs 48.9 Gy), the left 
optic nerve maximum point dose (56.3 vs 50.1 Gy) and the mean 
chiasm dose (46.1 vs 34.5 Gy) were in favor of the proton plan. In 
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the right cochlea maximum point dose (65.6 vs 70.7 Gy) were 
in favor of the photon plan. In Case 6, the brainstem maximum 
point dose (13.8 Gy vs 1.8 Gy), the chiasm maximum point dose 
(9.0 Gy vs 0.9 Gy), the left optic nerve maximum point dose (6.3 
Gy vs 0.8 Gy), the right optic nerve maximum point dose (4.7 Gy 
vs 0.7 Gy), and the mean chiasm dose (6.4 Gy vs 0.7 Gy) were in 
favor of the proton plan.
V100, V90 and V72
The accumulated dose of 100 Gy was reached in seven out of 
nine cases (77.8%) for both the proton and the photon plans. In 
all these cases, the V100 was larger for the proton plans than the 
photon plans, while the dose coverage of the PTV was equal. The 
mean V100 was 6.9 ± 9.1 and 10.3 ± 9.6 ccm for the accumulated 
photon and proton plan, respectively (p < 0.05). Similarly, the 
V90 and V72 volumes were significantly smaller for the photon 
plans than for the proton plans (Figure 3). The V90 was 32.7 ± 
34.7 ccm for photons vs 43.8 ± 41.4 ccm for protons (p < 0.05). 
The V72 was 57.6 ± 71.4 ccm for photons vs 70.5 ± 65.5 ccm for 
protons (p < 0.05).
Integral dose
For the re-irradiation plans only, the integral dose and the total 
dose to the brain excluding the PTV were analyzed (Table 3 and 
Figure 4). In all nine cases, the integral dose was lower for the 
proton plans than for the photon plans. The mean integral dose 
for protons was reduced by 48.6% with respect to the photon 
plans (12.4 ± 12.7 Gy vs 6.4 ± 6.0 Gy, p < 0.01). The mean total 
dose received by the brain, excluding the PTV, was 57.7% less 
for protons compared to photons (6.4 ± 6.2 Gy vs 2.7 ± 2.5 Gy, 
p < 0.01).
Case specific analysis
Despite the volumes receiving high doses (V100, V90 and V72) 
being smaller for the photon plans (Figure  3) and the integral 
doses being smaller for the proton plans, the area in which a 
specific plan shows superiority is largely dependent on the size, 
location and shape of the target (Figure 5). While Case 6 had a 
larger PTV (101.9 ccm) protruding deeper into the brain with 
concave parts, Case 7 had a smaller, spherical and more super-
ficially located target (14.6 ccm). Even though, the high dose 
volumes, i.e. V100 and V90, are still bigger for the proton plan in 
Case 6 (26.2 ccm vs 29.1 ccm and 104.0 vs 131.2 ccm), the V72 
(224.3 ccm vs 220.6 ccm, Figure 3) and the integral dose brain 
dose are lower (17.7 Gy vs 8.7 Gy, Figure 4).
DiScuSSion
The goal of this study was to provide a dosimetric comparison 
between protons and photons for re-irradiation of recurrent 
meningioma. While the brain volume receiving 100, 90 and 70 
Gy was higher for the proton plans, significantly better dose 
sparing of average mean and maximum doses to the majority of 
OARs could be achieved for protons. Additionally, the integral 
dose and total brain dose were roughly 50% lower for the proton 
plans compared with the photon plans.
Brain barrier disorder is a frequently observed late side-ef-
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within a few years after treatment.39–43 The probability to develop 
a brain barrier disorder depends on the prescribed RT dose and 
the volume affected by high RT doses as mentioned.44,45 It has 
been shown that the incidence of brain barrier disorders increases 
from 5 to 10% at doses of 72 vs 90 Gy.28 Schlampp et al identified 
temporal lobe necrosis in 5% of the patients who received heavy 
ions with RT doses of 68.8 Gy (RBE) on the skull base vs 50% 
when irradiated with 87.3 Gy (RBE).44 Thus, for accumulated 
doses up to 100 Gy EQD2, this rate cannot be disregarded;20,46 the 
higher the volume receiving these doses, the higher the chances 
of a brain necrosis. Many of the proton planning studies reported 
that proton plans achieve higher conformity due to the lack of 
exit dose and the steep gradient in the distal edge and are, there-
fore, better at sparing previously irradiated areas.4,16,17,26–33 Our 
results showed that the V100, V90 and V72, predictors of brain 
injury, were all in favor to the photon plans showing superior 
high dose conformity. Similar results were found in a proton–
photon comparison study in rectal cancer by Berman et al, which 
used the double scatter technique35 and in a dosimetric evalu-
ation in non-small cell lung cancer performed by Macdonald 
et al..47 The reason for the inferior dose gradient of the proton 
plans in the current study are the inferior lateral penumbra of 
pencil beam scanning and the range shifter that was used in all 
of the plans. The lateral penumbra of spot scanned proton beams 
is characterized by a less steep dose fall-off compared to the dose 
fall-off at the distal edge and is considered inferior to what can be 
achieved with photons. Especially, in the lower energies used for 
superficial dose deposition the lateral penumbra is wider.48 The 
majority of the dose bath surrounding the target is made up by 
the lateral penumbra. Therefore, the high dose area surrounding 
the target will only have a real benefit of the Bragg peak on the 
side—distally from the proton beam. In the case of re-irradiation, 
where one wants to keep the high dose area as small as possible 
isotropically around the target, the typical physical character-
istics of protons need to be reconsidered. The use of the range 
shifter will have an impact on the spot size.49 The typical spot 
size used for these plans was 0.425 cm. An increase in the spot 
size will result in a spread out of the dose gradient. Regarding the 
range shifter used in these plans, the dose gradient from 100 to 
50% of the dose will be approximately 25–30% narrower when 
no range shifter is used. Without the range shifter, there will 
still be a slight advantage for the high dose regions for photons, 
but the intersect of the integral dose will be shifted towards the 
right and the dosimetric advantage will start at a higher dose. 
Figure 1. Three-dimensional representation of the tumor locations of the primary treatment.
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The dose gradient could be slightly improved by adjusting the 
settings for the NTO. However, this would come at the expense 
of the coverage and homogeneity of the dose in the target; thus, 
this possibility was limited.
Dose constraints for critical structures in the brain have been 
elaborated by the Radiation Therapy Oncology Group and 
Quantec after the pioneering work of Emami et al..25,50–52 In 
the current study, OAR sparing was almost identical between 
protons and photons. In fact, the absolute difference in dose to 
OARs was only potentially clinically relevant on an individual 
level. In two cases, protons were in favor, and in one case, 
photons were favorable. In the remaining six cases, dosimetric 
results were comparable. More recently, it has been discovered 
that, apart from fraction size and radiation volume,53,54 the 
doses to the hippocampi are correlated with cognitive impair-
ment.55,56 While, the proton plans achieved a better hippo-
campal sparing in our analysis, the absolute difference was 
negligible. However, the integral dose to the brain, another 
predictor of neurocognitive impairment, was clearly superior 
with the proton plans.
Table 3. Overview of the dose volume analysis on the EQD2 accumulated plans
EQD2 of accumulated 
photon reirradiation plan 
(stdv)






Brain–brainstem Max dose 105.1 (±20.4) 105.3 (±19.9) not significant
Mean dose 15.5 (±6.8) 13.7 (±5.8) p < 0.01
Brainstem Max dose 24.3 (±30.0) 21.7 (±31.8) not significant
Mean dose 8.2 (±10.0) 7.1 (±9.4) p < 0.01
Chiasm Max dose 20.9 (±24.4) 18.5 (±23.2) p < 0.01
Mean dose 13.2 (±15.9) 11.0 (±13.5) p < 0.01
Optic nerve left Max dose 17.6 (±22.6) 16.0 (±21.8) p < 0.01
Mean dose 10.8 (±14.4) 9.9 (±13.9) p < 0.01
Optic nerve right Max dose 18.8 (±23.8) 18.3 (±24.7) not significant
Mean dose 13.0 (±18.4) 12.3 (±18.2) p < 0.01
Hippocampus left Max dose 19.3 (±20.1) 16.2 (±19.6) p < 0.01
Mean dose 9.5 (±11.7) 7.5 (±11.0) p < 0.01
Hippocampus right Max dose 24.9 (±33.4) 23.4 (±33.6) p < 0.05
Mean dose 14.8 (±20.7) 14.7 (±24.4) not significant
Pituitary gland Max dose 19.5 (±24.8) 17.6 (±23.6) p < 0.01
Mean dose 15.1 (±20.6) 13.9 (±20.2) p < 0.01
Cochlea left Max dose 10.1 (±16.8) 9.3 (±16.8) p < 0.01
Mean dose 8.4 (±14.1) 7.6 (±14.0) p < 0.01
Cochlea right Max dose 13.0 (±22.1) 12.7 (±23.7) not significant
Mean dose 11.3 (±20.4) 10.7 (±20.8) not significant
Volume in ccm (stdv)
V100 5.4 (±8.5) 8.0 (±9.5) p < 0.05
V90 25.4 (±33.4) 30.1 (±40.7) p < 0.05
V70 51.2 (±69.5) 62.6 (±65.6) p < 0.05
Integral dose in Gy (stdv) to the single reirradiation plans
Photons Protons
Total integral dose 12.4 (±12.7) 6.4 (±6.0) p < 0.01
Dose to brain-PTV 6.4 (±6.2) 2.7 (±2.5) p < 0.01
Conformity index of the reirradiation plans
Conformity index 0.63 (±0.09) 0.55 (±0.1) not significant
      PTV,       
planning target volume.      
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Therefore, determining the preferable treatment modality is 
extremely case specific. This result demonstrates the impor-
tance of individual plan comparison for optimal patient selec-
tion for proton therapy, but individual plan comparison costs 
time and resources; thus, is not desirable for every patient. The 
goal should be to determine guidelines, in which, based on case 
specific properties, patients could be selected for plan compar-
ison. In other words, we should be able to select, prior to plan 
comparison, which patients will definitely benefit from protons 
and which patients will definitely not. In the remaining "border-
line" cases plan comparison can provide the solution. In specific 
cases in this study, we noticed that the advantage for protons 
is associated with the size and shape of the tumor as well as 
the location and the relative distance to certain OARs. Conse-
quently, in a recent study on reirradiation with particle therapy, 
published by El Shafie et al, the majority of lesions where located 
at the skull base, which is typically is a good location for particle 
therapy.34 In silico studies could help to discover and elaborate 
such properties to determine specific guidelines based on size, 
shape and location of the target. Together with other parameters 
such as prognosis, patient condition and the type of alternative 
photon treatment it can be determined, if a specific case should 
be treated with photons, protons or needs a plan comparison.
There are a few limitations to our study. For an optimal compar-
ison between the two modalities we have chosen the same PTV, 
planning platform and fractionation scheme for both the proton 
and photon plans. In an actual clinical setting, the margins to 
get to a PTV might differ for a photon or a proton treatment, 
resulting in different target sizes. Also, the fractionation of 15 × 3 
Gy might not be the optimal choice for both photon and proton 
re-irradiations. The treatment planning data of the photon plans 
are performed on a clinically used and commissioned platform. 
The beam data is adopted from the actual re-irradiated plan and 
clinically verified. The proton plans, however, were performed on 
modeled beam data and these plans were not verified for clinical 
Figure 2. Plots of the max and mean doses of the accumulated EQD2 plans with photons and protons for different organs at risk.
Figure 3. Bar plots of the volumes outside the PTV receiving 100, 90 and 72 Gy (EQD2) in accumulated dose for the photon plans 
(blue bars) and the proton plans (green bars). PTV, planning target volume.
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use. Furthermore, only one range shifter of 5 cm thickness was 
available, while in some cases this might have been abundant.
concluSion
The dosimetric results of the accumulated dose for a re-irradi-
ation with protons and with photons were very similar in this 
cohort. In general, the photon plans had a steeper dose falloff 
directly outside the target and were superior in minimizing the 
high dose volumes. The proton plans achieved a lower inte-
gral dose. Clinically relevant OAR sparing was extremely case 
specific, and it is recommended that the treatment modality 
should be assessed on an individual basis.
Figure 4. Bar plots of the integral dose of the re-irradiation plans. PTV,planning target volume.
Figure 5. Dose difference mapping of the photon minus the proton re-irradiation plans of Case 6 and Case 7.
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